Asthma: Effect of genotype on Response to Therapy in the Emergency Department by Henderson, Sean O. et al.
Volume VIII, n o . 3  :  August 2007                                                 73                                      Western Journal of Emergency Medicine
Sean O. Henderson MD* ⁪
Vannita Simma-Chiang* 
Chi Lee MD*
Kirsten Calder MD*
Wendy J. Mack PhD ⁪
INTRODUCTION
   Asthma accounts for more than 1.5 million Emergency 
Department (ED) visits, one-third of whom are admitted, and 
more than 5,500 (0.4%) deaths per year.1 In the setting of 
acute	asthma	exacerbation	in	the	ED,	inhaled	β2-adrenergic	
agonists, such as albuterol, are the mainstay of treatment. 
Unfortunately, wide variation exists in how individual patients 
respond to therapy, a phenomenon well known to emergency 
physicians.		The	finding	that	there	are	common	functional	
genetic	variants	of	the	β2-	adrenoreceptor	(β2AR)	has	led	
to the suggestion that response to therapy may vary from 
individual to individual depending upon their genotypic 
makeup.2,3,4,5,6
   Single nucleotide polymorphisms (SNPs) are common, 
single-base pair variations in the DNA. There are some 1.4 
million SNPs in the human genome, 60,000 of which are in 
coding	regions.	The	β2AR	gene	is	located	on	the	long	arm	
of	chromosome	5,	and	thirteen	SNPs	have	been	identified	
in the gene. Two closely linked coding polymorphisms at 
amino acid positions 16 (A46G) and 27 (C79G) are common 
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Objective: We	examined	the	effect	of	two	β2-adrenoreceptor	(β2AR)	polymorphisms	(A46G	and	C79G)	
in asthmatics presenting to the Emergency Department (ED) in relation to their response to standard 
therapy measured by change in Forced Expiratory Volume at one second (FEV1). Our hypothesis was 
that	the	polymorphisms	in	the	β2AR	gene	would	predict	clinical	response	to	therapy	with	46G	and	79C	
displaying decreased response to inhaled therapy. 
Methods: This was a pilot feasibility study of a convenience sample of patients seen in the ED for 
acute exacerbation of asthma. Baseline data collected included: age, gender, ethnicity, vital signs, 
baseline FEV1, body mass index (BMI), smoking history and medications taken prior to arrival to the 
ED. Patients received standard ED care and FEV1 was measured after each treatment. Blood was 
taken and genotyped.
Results: Fifty-three patients were enrolled over a three-month period. Using mean improvement in 
FEV1	from	baseline	to	the	first	treatment	as	the	primary	outcome	of	interest,	we	performed	multivariable	
linear regression analyses, with the FEV1 change as the dependent variable. When modeled as an 
ordinal	covariate	representing	the	number	of	G	alleles	present,	there	was	a	significant	positive	trend	
for the C79G locus (p=0.035). Those who were GG homozygotes had a 0.284 L/min improvement in 
FEV1 (31%) after their initial albuterol treatment compared to 0.123 L/min (12%) in those who were CC 
homozygotes. This represents a 2.5 times relative difference and a 19% actual difference.  Genotypes 
at the A46G locus were not associated with FEV1 change.
Conclusion:	In	this	pilot	study	of	ED	patients	with	acute	asthma	exacerbation,	there	was	a	significant	
effect of genotype on response to therapy.  
[WestJEM. 2007;8:73-77.]
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β2AR	C(79)G	probes	used	to	detect	each	of	the	alleles	are:	
GTCACGCAGCAAAGGGACG and 
GTCACGCAGGAAAGGGACTG (21).
Statistical Analysis
			Outcome	variables	included	five	separate	measurements	
(one measurement prior to treatment and four measurements 
after treatment 20 minutes apart) of FEV1. Data analysis 
related the degree of improvement in FEV1 to the 
polymorphisms seen in the ß2-adrenoreceptor at the two loci 
in question—A46G (AA homozygyotes, AG heterozygotes, 
and GG homozygotes) and C79G (CC, CG, and GG). 
Demographic variables including, age, gender, ethnicity, 
smoking history, height, weight, body mass index, and 
medication	profile	were	also	considered	in	our	analysis.
   Our analyses consider the absolute difference between 
baseline FEV1 (immediately before the	first	inhaled	
treatment) and that measured at time #1 (immediately after 
the	first	inhaled	treatment)	as	the	primary	outcome	measure	
of interest since it was noted in exploratory analyses that 
subsequent FEV1s (at post-treatments #2 – 4) were highly 
correlated	with	the	first	post-treatment	measurement,	FEV1	#1	
(p-value	for	all	<0.0001	with	Pearson	correlation	coefficients	
ranging from 0.92 – 0.96).   
   We used analysis of variance to test for differences in the 
mean FEV1 change among the genotypes at each locus. 
To adjust for potentially confounding covariates, we also 
performed multivariable linear regression analyses, with the 
FEV1	change	(first	post-treatment	minus	baseline)	as	the	
dependent variable. The independent variables included the 
two genetic loci as well as the covariates listed above. In the 
regression model, the genotypes were modeled as the number 
of ‘G’ alleles present (0,1,2).  
RESUlTS
   Fifty-three patients were enrolled over a three-month period 
(Table 1). Twenty-one of these were male and the mean age 
was 39.7 years (range 19-57 years). Mean baseline FEV1 
was 1.17 L/min (range 0.33 to 2.59 L/min) and improved to a 
mean	of	1.42	L/min	(range	0.29	–	3.15)	after	the	first	inhaled	
treatment. Our preliminary analyses revealed that particular 
polymorphisms were highly correlated such that the presence 
of a given allele at one locus could predict the allele at the 
other locus (i.e., the two were in linkage disequilibrium). 
Specifically,	individuals	homozygous	for	the	‘A’	allele	at	locus	
46 were in all instances homozygous for the ‘G’ allele at locus 
79. 
   Those individuals who were 79GG homozygotes had a 
0.284 L/min improvement in FEV1 (31%) after their initial 
albuterol treatment compared to 0.123 L/min (12%) in those 
who were CC homozygotes.  This represents a 2.5 times 
relative difference and a 19% actual difference (Figure 1). 
in the general population and in controlled outpatient trials 
have demonstrated to modify the phenotypic response to 
β2-	agonists	(46G	and	79C	being	associated	with	decreased	
response to inhaled therapy).2  
   In this feasibility study, we examined these two SNPs in an 
asthmatic population presenting for acute care in the ED. Our 
goal was to determine whether different genotypes at these 
two	genetic	loci	affected	response	to	β2-agonists	as	measured	
by forced expiratory volume at one second (FEV1).
METHODS
   This was an IRB-approved feasibility study of a convenience 
sample of patients seen in the ED for acute exacerbation 
of previously diagnosed asthma. Patients for this study 
were recruited in the ED of a large urban facility serving a 
local population of some 1.5 million individuals. Patients 
meeting inclusion criteria were consented and baseline 
data were obtained, including, age, ethnicity, height (cms) 
and weight (kg), BMI (kg/m2), smoking history (current, 
past, never), medication used prior to arrival, and past 
medical history.  An initial set of vital signs including blood 
pressure (mmHg), respiratory rate and pulse rate as well as 
pulse oximetry (%) was collected. Prior to the initiation of 
therapy we also measured FEV1 using incentive spirometery 
(MicroSpirometer) with the best of three consecutive 
measurements.  
   Patients then received standardized care with albuterol-
inhaled therapy, receiving 5.0 mg via a hand-held nebulizer 
every 20 minutes for a total of four treatments. Patients also 
received	60	mg	of	prednisone	P.O.	after	the	first	inhaled	
treatment. Patients were not administered any other inhaled 
medications until after completion of the study protocol. 
Immediately after each inhaled treatment, the patient was 
reexamined and FEV1 measurements were obtained.  
   Study patients also underwent phlebotomy to obtain one 
10ml green top tube (heparinized vacutainer) for genotype 
testing. For processing, we utilized an automated specimen 
component dispensing machine (the Cryo-Bio System). DNA 
extraction was accomplished on an ongoing basis using the 
Qiagen 96 DNA Blood Biorobotic Kit. 
   Genotyping assays were performed using the Taqman assay. 
Allele-specific	probes	for	use	in	the	TaqMan	assay	were	
designed for each of the polymorphic sites within the genes of 
interest.	The	oligonucleotide	primers	for	amplification	of	the	
polymorphic region are: 
5’: CCCAGCCAGTGCGCTTACCT and 
3’: CCGTCTGCAGACGCTCGAAC (18).
β2AR	A(46)G	probes	used	to	detect	each	of	the	alleles	are:	
GCACCCAATGGAAGCCATG and 
GCACCCAATACAAGCCATG (21).
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Table 1.  Characteristics of the individuals included in FEV analyses (n=54)
Category
Predictor
Number * (#) or
Mean
Percent (%) or
Std. Dev.
Range
DEMOGRAPHICS
Ethnicity
African-American 11 20.4%
Caucasian 6 11.1%
Latino/Latina 36 66.7%
Age 39.9 10.8 19-57
Gender
Male 21 38.9%
Female 32 59.3%
GENOTYPE
A46G Genotype1
AA 13 24.1%
AG 29 59.3%
GG 11 20.4%
C79G Genotype2
CC 4 7.4%
CG 12 22.2%
GG 38 70.4%
COVARIATES
Smoking
Current 17 31.5%
Past 16 29.6%
Never 20 37.0%
Body Mass Index
Height (cm) 167.8 31.5 142.2-193.0
Weight (kg) 89.0 25.6 52-163.6
BMI (kg/m2) 31.6 8.3 18.5-56.6
Inhaled Asthma Medications Prior to Arrival
None 18 33.3%
Yes 35 66.6%
OUTCOME
Forced Expiratory Volume
Baseline FEV (n=50) 1.16 0.63 0.33-2.59
FEV, time #1 (n=52) 1.41 0.68 0.29-3.15
FEV, time #2 (n=52) 1.54 0.67 0.27-2.95
FEV, time #3 (n=48) 1.53 0.67 0.25-3.17
FEV, time #4 (n=38) 1.62 0.76 0.25-3.17
Disposition
Home 53 100%
1A46G Genotype Frequency  A: 0.52, G: 0.48
2C79G Genotype Frequency  C: 0.19, G: 0.81
*Numbers may not add to total sample size due to missing genotype data.
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When modeled as an ordinal covariate representing the 
number	of	‘G’	alleles	present,	there	was	a	significant	positive	
trend for FEV1 change with increasing numbers of ‘G’ alleles 
at the C79G locus (p=0.035). Genotypes at the A46G locus 
were not associated with FEV1 change in either regression 
model.
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Figure 1.  Mean values of FEV difference between 
baseline	and	Time	1	stratified	by	locus	and	genotype.95%	
confidence	intervals	are	represented	by	the	error	bars.
DISCUSSION
			β-agonists	are	the	most	commonly	prescribed	asthma	
medications and the mainstay of therapy in the treatment of 
acute exacerbation in the ED.8 The candidate gene approach, 
which has proved so challenging for complex disease 
processes such as hypertension, diabetes and cancer, has 
been fairly successful in identifying variation involved in 
the	treatment	of	asthma.	SNPs	have	been	identified	that	have	
pharmacologic	implications	with	regards	to	response	to	β2 
agonists, muscarinic antagonists, 5-LOX inhibitors, CysLT1 
antagonists, glucocortocoids, and theophylline.6 Two of the 
multiple	β2-agonists SNP’s (A46G and C79G) described in 
the literature are more common than the others and thus, we 
believe, more clinically relevant.2,6,7
			The	first	polymorphism,	A46G,	has	been	linked	to	
higher levels of receptor down regulation after exposure 
to	long-term	β2-agonist therapy.3,4 Studies have shown 
that patients with a ‘G’ allele have increased nocturnal 
asthma symptoms, higher airway reactivity, and decreased 
response	to	β2-agonist therapy.5 In the setting of an acute 
asthma exacerbation, these patients may need to resort to 
alternative forms of management such as corticosteroids or 
anticholinergics. It has also been suggested that individuals 
who die due to their asthma represent a group of 46G 
homozygotes, brittle asthmatics with desensitization of their 
β2 receptor.9 
   The second polymorphism, C79G, appears to serve in 
protection against desensitization and/or down regulation of 
the receptor.3,4 Patients with the 79G polymorphism exhibit 
decreased bronchial hyperactivity.  Of note, when both the 
46G and 79G polymorphisms were present, 46G activity was 
dominant	over	79G	in	down	regulating	β2-adrenoreceptors 
and more prevalent in moderate vs. mild asthmatics.10 
   In our study, as patients increased the number of copies 
of	79C	in	their	β2AR gene, their response to inhaled therapy 
of	β2-agonists decreased by almost 20%. Interestingly, we 
were not able to demonstrate an effect of the A46G locus on 
patients’ response to albuterol therapy as measured by FEV1. 
One explanation for this may be tachyphylaxis in these 
acutely	stressed	asthmatics.	Given	that	the	β2AR in these 
patients is most likely “pre-desensitized” by endogenous 
epinephrine and norepinephrine, the lack of a measurable 
difference is not unexpected.  
lIMITATIONS
   The primary limitation of this pilot study is the small 
number of individuals who were 79C homozygotes. In 
addition	the	results	may	have	been	influenced	by	the	large	
percentage of patients who received medications prior to 
contact with EMS or the ED. Their response to therapy may 
have been attenuated by these prior medications.  
CONClUSION
  	In	this	study	of	acute	asthmatics	we	found	a	significantly	
higher rate of improvement for those patients who were 
79GG	homozygotes	in	the	β2AR gene when compared to 
79CC homozygotes. While the need to have information 
about a patient’s genotype in an acute care setting such 
as the ED may not be self-evident, it is the promise of 
effective	patient-specific	therapies	and	the	hope	of	obtaining	
prognostic information from a patient’s genotype that 
appeals most to the physicians involved in the acute care 
of patients. Such information may allow a goal-directed 
approach for individual patients and will allow the 
practitioner to predict the clinical course over the initial two- 
to four-hour time period of emergency care. In the setting of 
asthma, the long term potential of such information may be 
measured by fewer intubations, fewer hospitalizations and 
fewer deaths.1
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